Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.2% – Here’s Why

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 3.2% during mid-day trading on Thursday . The company traded as low as $5.96 and last traded at $5.98. Approximately 3,884,146 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 25,000,162 shares. The stock had previously closed at $6.17.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of research analyst reports. Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Up 6.9 %

The firm has a market cap of $2.55 billion, a P/E ratio of -4.15 and a beta of 0.85. The business’s fifty day moving average price is $7.54 and its two-hundred day moving average price is $7.02. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.42) EPS. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RXRX. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals in the 4th quarter worth $27,000. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares during the period. Farther Finance Advisors LLC raised its holdings in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares during the period. Finally, KBC Group NV raised its holdings in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after acquiring an additional 3,377 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.